Doxorubicin (DOX) is an effective anthracycline used in chemotherapeutic regimens for a
variety of haematological and solid tumors. However, its utility remains limited by its well …

Doxorubicin (DOX) is one of the most widely used and successful antitumor drugs, but its
cumulative and dose-dependent cardiac toxicity has been a major concern of oncologists in …

Doxorubicin (Dox) is a cytotoxic drug widely incorporated in various chemotherapy
protocols. Severe side effects such as cardiotoxicity, however, limit Dox application …

Doxorubicin is a chemotherapeutic drug used for the treatment of various malignancies;
however, patients can experience cardiotoxic effects and this has limited the use of this …

Doxorubicin (DOX)-induced cardiotoxicity has been a well-known phenomenon to clinicians
and scientists for decades; however, molecular mechanisms underlying DOX cardiotoxicity …

Drug-induced cardiotoxicity is a life-threatening side effect of doxorubicin (DOX) treatment
that impacts patient prognosis and survival. In the majority of cases, the acute clinical form …

Doxorubicin (DOX) is an effective anti-cancer agent. However, DOX treatment increases
patient susceptibility to dilated cardiomyopathy. DOX predisposes cardiomyocytes to insult …

Doxorubicin (Dox) is an effective chemotherapeutic agent, however, its use is limited by
cardiotoxicity. The mechanisms causing cardiotoxicity have not been clearly elucidated, but …

Aims Active autophagy has recently been reported in doxorubicin-induced cardiotoxicity;
here we investigated its pathophysiological role. Methods and results Acute cardiotoxicity …

Despite recent advances in cancer therapy, anthracycline-based combination therapy
remains the standardized first-line strategy and has been found to have effective antitumor …